The subsidiary of Beijing Hotgen Biotech Co.,Ltd. (ASX: 688068) has received a significant regulatory green light.

Its subsidiary, Beijing Shunjing Biopharmaceutical Technology Co., Ltd., has obtained a Drug Clinical Trial Approval Notice from the National Medical Products Administration.

This notice grants approval for the clinical trial application of the innovative drug SGT003 Injection.

The drug, SGT003 Injection, represents a pioneering achievement developed on Shunjing's proprietary NexTreg™ technology platform.

It is distinguished as the first-in-human, novel bispecific antibody candidate to enter clinical studies globally with its unique mechanism.

The core innovation of SGT003 lies in its ability to precisely clear regulatory T cells within the tumor microenvironment, thereby activating anti-tumor immunity.

This targeted approach not only focuses on tumor tissue and modulates the tumor microenvironment to stimulate the body's own immune response against cancer cells but also aims to reduce immune activation-related toxic side effects associated with the CTLA-4 pathway.

It holds the potential to effectively treat a broad patient population with solid tumors that are resistant or unresponsive to conventional therapies.

SGT003 is anticipated to become a foundational therapy in the field of tumor immunotherapy.